McKesson Stock Price, News & Analysis

On July 22, 2022, McKesson Corporation (NYSE:MCK) declared a regular dividend of $0.54 per share, marking a 15% increase from the previous $0.47. The dividend will be payable on October 3, 2022, to shareholders of record as of September 1, 2022. CEO Brian Tyler emphasized the dividend increase reflects robust cash flow and the company’s confidence in its long-term growth strategy. Notably, this marks the sixth consecutive year of dividend increases for McKesson.

McKesson Corporation (NYSE: MCK) will announce its first quarter fiscal 2023 financial results on August 3, 2022, after market close. The company will conduct a live webcast at 4:30 PM Eastern Time to discuss the results. Investors can access the webcast and related financial documentation on the company’s Investor Relations website. McKesson is committed to improving health outcomes and providing affordable healthcare solutions through partnerships with various stakeholders in the healthcare sector.

McKesson Corporation and HCA Healthcare have announced a joint venture to combine their oncology research arms, US Oncology Research and Sarah Cannon Research Institute, enhancing clinical trial access and drug development. This venture aims to expand oncology research, streamline trial matching for patients, and improve access, particularly for underserved communities. McKesson will hold 51% ownership, with the joint venture expected to close in 2022. Financial details remain undisclosed, and the agreement is subject to regulatory approvals.

McKesson Corporation and HCA Healthcare have announced a joint venture to combine their oncology research efforts, enhancing clinical trials and treatment options for cancer patients. The venture will merge McKesson’s US Oncology Research with HCA’s Sarah Cannon Research Institute, aiming to improve access and accelerate cancer drug development, especially in underserved communities. McKesson will hold a 51% stake and operating control. The deal is expected to close in 2022, pending regulatory approval and customary conditions.

McKesson Corporation (NYSE: MCK) announced its fiscal 2022 fourth-quarter financial results, which are accessible through its Investor Relations website. A live webcast of the earnings conference call is scheduled for May 5 at 4:30 PM ET, allowing investors to review the results in detail. McKesson aims to enhance healthcare accessibility and affordability through partnerships with various healthcare entities. More information is available on their official website.

AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have settled opioid-related claims with the Washington Attorney General, agreeing to pay up to $518 million. This payment resolves lawsuits filed by the state and its subdivisions, allowing for the dismissal of ongoing litigation. The settlement aligns with a previously announced agreement effective April 2, 2022, aimed at addressing a significant portion of opioid claims against the distributors. The companies dispute the allegations but see this as steps toward broader resolutions and relief for impacted communities.

The Board of Directors of McKesson Corporation (NYSE:MCK) has declared a regular dividend of 47 cents per share of common stock. This dividend will be payable on July 1, 2022, to stockholders of record on June 1, 2022. McKesson Corporation is a leader in healthcare services, focusing on enhancing health outcomes through partnerships with various stakeholders in the industry, including biopharma companies and care providers. For further information, visit McKesson.com.

McKesson Corporation (NYSE: MCK) has successfully closed the sale of its UK businesses to AURELIUS, enhancing its focus on streamlining operations and exiting the European market.

The company is set to report its fourth quarter fiscal 2022 financial results on May 5, 2022, with a live earnings conference call at 4:30 PM ET. Further comments on the sale will be provided during this call, with the earnings release and financial details accessible on McKesson's Investor Relations website.

McKesson Corporation (NYSE: MCK) announced the election of W. Roy Dunbar as a new director and member of the Audit and Governance Committees, effective April 1, 2022. This expands the board from 11 to 12 members, with 11 being independent. Dunbar brings extensive experience from roles at Network Solutions, Mastercard, and Eli Lilly, focusing on technology, operations, and sustainability. His addition is expected to enhance the board's oversight, particularly in oncology, biopharma, data governance, and cybersecurity.